Cardiovascular Diseases Clinical Trial
— LIVES-GPOfficial title:
Lifestyle InterVEntion Study in General Practice: LIVES - GP
NCT number | NCT06286345 |
Other study ID # | 17644 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 1, 2023 |
Est. completion date | July 1, 2025 |
Patients with depression are at a substantially increased risk of chronic physical disease including cardiovascular disease. This may be attributed primarily to an unhealthy lifestyle related to their disorder. Interestingly, the unhealthy lifestyle feeds back to decreased quality of life and increased depressive symptoms, thus creating a hazardous vicious circle. Consequently, there is a great potential for 'Lifestyle Medicine' for depression. Yet, it is known that patients with depression often have motivational and self-management problems. Therefore an 18 session multimodal lifestyle intervention (MLI) specifically tailored to the needs of depressed patients was developed and piloted in mental health care, with promising results. This research aims to investigate using a process evaluation the feasibility of this MLI in general practice because this is the setting where the majority of patients with depression are treated and results from mental health care are unlikely to apply.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 1, 2025 |
Est. primary completion date | March 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of depressive symptoms or depressive disorder in the past year as registered in the general practice electronic health record and coded according to the International Classification of Primary Care (ICPC) as P03 and P76, respectively, or currently treated for depressive symptoms or depressive disorder in general practice. - At least mild depressive symptom level according to the Quick Inventory Depressive Symptomatology-Self-Report (QIDS-SR) (score =6) - Body mass index = 25 kg/m2 or increased waist circumference (>88 cm (women) of >102 cm (men)). Exclusion Criteria: - Current treatment in mental health care (GGZ in Dutch) - Severe somatic / neurological disease at the discretion of the GP - Currently participating in another lifestyle intervention - Insufficient proficiency in Dutch - Inability to read and write |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen | GGZ Drenthe Mental Health Institution |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reach of GLI-LEEF | Reach of GLI-LEEF as defined as the number of individuals who are willing to participate in this study | 12 months | |
Primary | General practice adoption of GLI-LEEF | General practice adoption of GLI-LEEF as defined by the number of general practices that are willing to implement GLI-LEEF in this study | 12 months | |
Primary | General practitioner adoption of GLI-LEEF | General practice adoption of GLI-LEEF as defined by the number of general practitioners that are willing to implement GLI-LEEF in this study | 12 months | |
Primary | Lifestyle coach adoption of GLI-LEEF | Lifestyle coach adoption of GLI-LEEF as defined by the number of lifestyle coaches that are willing to implement GLI-LEEF in this study | 12 months | |
Primary | Adherence to GLI-LEEF | First aspect of implementation is adherence to GLI-LEEF which is defined by the number of sessions attended by the participant out of the total of 18 sessions | 18 weeks | |
Primary | Drop-out from GLI-LEEF | Second aspect of implementation is drop-out from GLI-LEEF which is defined by the proportion of participants who decide to prematurely stop taking part in the intervention | 18 weeks | |
Primary | Barriers and facilitators of the GLI-LEEF implementation | Potential barriers and facilitators of the GLI-LEEF implementation will be identified using a qualitative approach by interviewing approximately 10 participants who dropped out and 10 who completed GLI-LEEF, if opportune | 18 weeks | |
Secondary | Body weight of the participant as assessed by a medical weight scale | Body weight in kilograms | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Body height of the participant as assessed by a stadiometer | Body height in meters | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Waist circumference of the participant as assessed using a tape meter line | Waist circumference in centimeters | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Diastolic and systolic blood pressure as assessed using a sphygmomanometer | Diastolic and systolic blood pressure in millimeters mercury | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Treatment success on several domains by according to the Outcome Questionnaire-45 (OQ-=45) | The OQ-45 runs from 0 to 180. The lower the score, the more successful treatment | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Recovery of the participant according to the Individual Recovery Outcomes - Counter (I.ROC) | The I.ROC is an instrument to quantitatively measure recovery. The total score runs from 12 to 72. Higher scores indicate better outcomes. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Wellbeing as assessed by the Mental Health Continuum Short Form (MHC-SF) | The MHC-SF measures emotional, social and psychological wellbeing. Its total score runs from 0 to 20. Higher score means better outcome. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Self esteem according to the Rosenberg Self-Esteem Scale (RSES) | The RSES is a widely used self-report instrument for evaluating individual self-esteem. The total score runs from 0 to 30. Higher score means worse outcome, i.e. less self-esteem. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Insomnia according to the Insomnia Severity Index (ISI) | The ISI assesses insomnia. The total score runs from 0 to 28. Higher score means worse outcome. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Quality of life according to the Recovering Quality of Life (ReQol) | This is a Patient Reported Outcome Measure assesses the quality of life for people with different mental health conditions. Its score runs from 0 to 80. Higher score means better outcome. | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) | |
Secondary | Health care consumption and productivity loss according to the Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P) | The TiC - P assesses health care consumption and productivity loss in patients with mental illness | Baseline, at the end of the intervention (18 weeks), and at the 6 months follow up (42 weeks after baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|